Pfizer: Hospira One2One will operate alongside CentreSource, initially...
The Hospira injectables unit – known as One2One – makes injectables has manufacturing facilities in McPherson, Kansas and Rocky Mount, North Carolina in the US.
The contract manufacturing organisation (CMO) also has production facilities in Liscate in Italy, Mulgrave in Australia, Chennai in India and Zagreb in Croatia.
A Pfizer spokeswoman told Outsourcing-pharma.com that the One2One business “will become part of Pfizer, but not part of CenterSource initially.”
The US drug giant also confirmed that all the One2One facilities, as well as the organisation’s head office in Lake Forest, Illinois will continue to operate independently.
When Pfizer announced plans for the $17bn (€15.2bn) takeover in February it cited Hospira’s generic injectables business along with its biosimilar development and production capabilities as the main drivers for the acquisition.
At the time Pfizer CEO Ian Read said: "Hospira’s business aligns well with our new commercial structure and is an excellent strategic fit for our Global Established Pharmaceutical business, which will benefit from a significantly enhanced product portfolio in growing markets."
Steroids and injectables
One2One provides contract custom development and finished-dose manufacturing of injectables to pharmaceutical industry customers.
Pfizer’s CentreSource business has a different focus.
The Pfizer division specialises in the production of steroid active pharmaceutical ingredients (APIs), antibiotics and the provision of custom manufacturing, process development and packaging services.
